Knee osteoarthritis often creeps up gradually, showing up as slight morning stiffness, a nagging ache after climbing stairs, or soreness after longer walks.

As symptoms progress, it can become harder to train regularly, manage busy workdays, and stay active without flare ups. When pain continues despite physiotherapy and strengthening, your doctor may suggest more targeted steps, such as a knee joint injection consultation, as part of a broader knee pain management plan in Singapore.

Autologous Protein Solution, commonly called APS, is an advanced injection option used for knee osteoarthritis pain. It is made from a small sample of your own blood, processed in clinic to concentrate specific anti-inflammatory proteins and growth factors, then delivered into the knee joint as a single intra-articular injection.

The nSTRIDE APS system is a point-of-care kit designed to produce about 2 to 3 cc of APS for knee injection. If you are weighing options, APS is often considered alongside treatments such as platelet-rich plasma injections, depending on your diagnosis, osteoarthritis severity, and activity goals.

Autologous Protein Solution is a biologic knee injection made from a small sample of your own blood. It is used for knee osteoarthritis and is prepared on the same day in the clinic using a dedicated processing system.

The nSTRIDE® APS kit is a sterile single-use device designed to process whole blood and concentrate selected anti-inflammatory cytokines and growth factors into an autologous injectable solution.

In simple terms, APS is different from a manufactured drug injection. It uses your own blood components, processed in a specific way, to deliver a higher concentration of proteins that may help calm an overactive inflammatory environment in the knee and support better function over time.

Osteoarthritis is not only “wear and tear”. It also involves inflammatory signalling inside the joint. It is a model where inflammatory proteins such as IL-1 and TNF-alpha contribute to cartilage degeneration and knee pain and states that these inflammatory proteins need to be stopped simultaneously to decrease pain and slow cartilage degeneration.

APS is described as introducing higher levels of anti-inflammatory factors that can block these inflammatory cytokines. IL-1 receptor antagonist, often written as IL-1ra and soluble TNF receptors, described as sTNF RI and sTNF RII, are part of the APS output profile.

While inflammatory balance is being restored, APS introduces anabolic growth factors such as IGF-1 and TGF beta 1, which are framed as beneficial for cartilage health.

A patient-friendly way to think about this is:

• Osteoarthritis pain is partly driven by inflammation signals inside the joint
• APS aims to deliver more of the body’s own “blockers” to calm those signals
• This may reduce pain, improve function and support a healthier joint environment over time

APS is created through a process of density-based separation followed by filtration-based concentration, producing a small-volume injectable solution enriched with anti-inflammatory proteins and growth factors. In laboratory studies, APS has been shown to dampen biological pathways linked to cartilage breakdown.

These findings include reduced production of catabolic enzymes in cartilage cells exposed to inflammatory signals such as IL-1 beta and TNF alpha, alongside a reduction in inflammatory cytokine release from activated immune cells and less tissue damage in cartilage models under inflammatory conditions.

Animal studies have also been used to examine potential effects on osteoarthritis related cartilage change. In a rat meniscal tear model, a single intra-articular APS injection was linked with less cartilage degeneration compared with saline. In a larger animal study involving horses with naturally occurring osteoarthritis, APS was associated with improved lameness scores compared with saline at two weeks, with additional owner-reported improvement noted at later follow-up.

In one safety-oriented study, 11 patients with knee osteoarthritis received a single intra-articular APS injection and were followed over time using WOMAC patient-reported measures. Across follow up, WOMAC pain scores were reported to improve. Within the same dataset, higher white blood cell concentration was linked with higher IL-1ra levels in the APS preparation, and the IL-1ra to IL-1 beta ratio was reported to be associated with greater WOMAC pain improvement at six months. In that group, 72.7 percent of participants met OMERACT OARSI criteria as high responders at six months.

A multicenter double blind randomised placebo-controlled pilot study also evaluated APS in 46 patients with unilateral knee osteoarthritis graded Kellgren Lawrence 2 or 3. Participants received a single ultrasound-guided intra-articular injection of APS or saline.

At 12 months, the reported change from baseline in WOMAC pain was 65 percent in the APS group and 41 percent in the saline group, with a reported p-value of 0.02. Safety findings were reported as comparable between groups, with no significant differences in adverse event frequency, severity, or relatedness. Overall, these results suggest APS may help reduce pain and improve function in selected patients with mild to moderate knee osteoarthritis, while recognising that individual response varies and outcomes cannot be guaranteed.

APS is designed as a point-of-care treatment, meaning it is prepared in the clinic from a small blood sample and injected during the same visit.

The final injection volume is typically about 2 to 3 cc, delivered directly into the knee joint as a single injection approach. Many clinical protocols describe symptom improvement beginning after one to two weeks and study follow-up suggests benefits may persist for up to 12 months in selected patients.

In real-world care, timelines and durability vary depending on osteoarthritis severity, body weight, activity load, biomechanics and how consistently rehabilitation is maintained.

Who may be suitable for Autologous Protein Solution for knee pain in Singapore

APS is usually discussed for people whose knee pain is primarily driven by osteoarthritis and remains limiting despite a structured conservative plan.

You may be a candidate if you have a confirmed diagnosis of knee osteoarthritis commonly mild to moderate on imaging and persistent pain that limits stairs, walking distance, squats, or sport participation. APS may also be considered if you have tried physiotherapy and strengthening with reasonable consistency but pain remains a barrier and you prefer a biologic option created from your own blood, delivered as a single injection approach.

Selection still needs to be individualised because knee osteoarthritis varies widely in pain drivers and severity.

Who may not be suitable for APS

APS is not intended for every cause of knee pain, so a consultation is needed to confirm that knee osteoarthritis is the primary pain source.

APS may be unsuitable or require extra caution if you have:

• Suspected or confirmed infection in the knee or elsewhere
• Unexplained significant swelling or systemic symptoms that need investigation
• Mechanical locking or catching symptoms suggest a meniscus tear
• Significant knee instability from a ligament injury
• Bleeding disorders or blood-thinning medication considerations that affect blood draw or injection safety
• End-stage osteoarthritis, where structural collapse dominates symptoms and surgical planning may be more appropriate

Your doctor should review your medical history, medications, examination findings and imaging before advising whether APS fits your situation.

What to expect during an APS consultation with Dr Gerard Ee at The Clifford Clinic

• Your visit starts with a doctor led assessment to confirm what is driving your knee pain and whether APS is appropriate.
• Symptom mapping: Dr Ee will clarify where the pain is, what triggers it, how long it has been present, and what treatments you have tried and for how long.
• Focused knee examination: assessment of range of motion, swelling pattern, point tenderness, stability, and functional loading tolerance such as stairs, squats, or walking.
• Imaging review when needed: X ray or MRI may be reviewed to confirm osteoarthritis severity and to rule out other causes such as meniscus mechanical symptoms, ligament instability, or tendon related pain.
• If knee osteoarthritis is confirmed, Dr Ee will discuss APS alongside other injection options, including hyaluronic acid viscosupplementation, corticosteroid injection when appropriate, and platelet rich plasma, based on your diagnosis and goals.
• The aim is to match the injection choice to your knee pathology and activity priorities, rather than using a one size fits all approach.
• You will leave with a clear, practical plan, including:
• What improvement markers to track
• Expected response timeline
• What to do in the first two weeks after the injection
• How to restart and progress strengthening and activity safely

APS compared with other knee injections

Hyaluronic acid injections are usually described as viscosupplementation, with the main aim of improving joint lubrication and reducing friction during movement.

APS is a blood-derived injection prepared from your own blood, designed to concentrate anti-inflammatory cytokines and growth factors. It is generally discussed as a way to address inflammatory drivers of osteoarthritis pain and support a more favourable joint environment.

Steroid injections can reduce inflammation faster in some flare-ups, but they are typically used for short-term symptom control. PRP protocols vary significantly between clinics, while APS is designed to concentrate white blood cells, platelets, and plasma proteins, including anti-inflammatory components such as IL-1ra and soluble TNF receptors, alongside growth factors.

Ultimately, the most suitable option depends on your diagnosis, osteoarthritis severity, symptom pattern, and treatment goals.